首頁 > 市場調查報告書 > 製藥

精神疾病

市場調查報告書

商品編碼

1410055

2023年至2028年睡眠障礙治療市場預測

Sleep Disorder Treatment Market - Forecasts from 2023 to 2028

出版日期: 2023年12月11日 | 出版商:

Knowledge Sourcing Intelligence | 英文 140 Pages | 商品交期: 最快1-2個工作天內

價格

簡介目錄

睡眠障礙治療市場預計將從2021年的145.1億美元成長到2028年的301.02億美元，複合年成長率為10.99%。

睡眠障礙的治療方法有很多種，取決於其性質和根本原因。然而，治療通常涉及醫療干預和用餐調整的組合。由於藥物、憂鬱症和憂鬱症增加等許多潛在因素導致睡眠障礙盛行率不斷增加，正在推動睡眠障礙治療市場的成長。此外，飲酒量的增加和氣喘患者數量的增加預計將進一步推動睡眠障礙治療市場的發展。

睡眠障礙增加

由於藥物、頻尿等多種因素，全球範圍內睡眠障礙的數量不斷增加，這是睡眠障礙治療市場的主要成長動力。例如，世界經濟論壇估計，2019 年，全球整體62% 的成年人認為自己晚上睡眠不足。此外，根據睡眠協會的數據，到 2022 年，多達 7,000 萬美國人將遭受睡眠問題。根據睡眠基金會 2022 年的一項調查，51.2% 的睡眠不足者聲稱他們的家庭有睡眠問題。此外，據睡眠醫生稱，失眠是美國最常見的睡眠障礙，影響著約三分之二的美國成年人。睡眠障礙的增加以及嗜睡和易怒等負面影響預計將推動睡眠障礙治療市場的發展。

憂鬱症和焦慮增加

失眠，或入睡或保持睡眠困難，是憂鬱症的典型症狀之一。此外，心理或身體創傷、代謝問題和其他健康問題也可能導致睡眠障礙。因此，人們的憂鬱症症狀正在增加，這對睡眠障礙治療市場產生了積極影響。根據世界衛生組織估計，全世界有 5% 的成年人患有憂鬱症，相當於約 2.8 億人。憂鬱症對美國的死亡率、發病率、殘疾和經濟支出有重大影響。例如，據 CDC 稱，2020 年，18.5% 的美國成年人被診斷出患有憂鬱症。

氣喘患者和酒精攝取量增加

氣喘藥物的刺激作用和其他醫療狀況（例如睡眠障礙）的存在都可能導致氣喘患者失眠。因此，氣喘患者數量的增加預示著睡眠障礙治療市場的擴大。根據世界衛生組織估計，2019年有4.55億人死於氣喘，2.62億人受到氣喘影響。根據氣喘醫學博士組織 (Asthma MD Organization) 的數據，在美國，氣喘佔急診室就診人數的 25%，每年有 200 萬人次就診。此外，根據酒精機制，酗酒會導致睡眠數量和品質出現問題，酗酒者經常失眠。例如，澳洲統計局估計，2020-21 年，18 歲以上的 500 萬澳洲人（四分之一）的飲酒量將超過澳洲成人建議攝取量。

市場機會

由於多種因素導致的睡眠障礙盛行率上升等成長要素為睡眠障礙治療市場的擴張提供了巨大的機會。此外，透過各機構組織的眾多宣傳活動，提高人們對睡眠障礙負面影響的認知，也進一步推動了睡眠障礙治療市場的發展，並提供了進入該市場的有利機會。過去 25 年來，睡眠基金會每年都會舉辦睡眠意識週 (R)。在睡眠意識週期間，基金會將共用人們過去一年睡眠狀況的深入資料，強調充足睡眠的好處以及睡眠如何改善健康和福祉。我們提供基於證據的指導。此外，疾病預防控制中心還授予了 2021 年至 2024 年為期三年的津貼，重點用於擴大對阻塞型睡眠呼吸中止症中止症的教育和認知。此外，生活水準的提高和健康意識的提高也推動了睡眠障礙治療市場的成長。

北美地區預計將大幅成長

預計在預測期內，北美地區將佔據睡眠障礙治療市場的很大佔有率。造成這一比例的因素包括對該疾病的認知提高、診斷率上升和忙碌的生活方式。根據美國心理學會（APA）的一項調查，2020年成年人的壓力程度為5.0分，分數範圍為1到10。過去兩年，Z 世代成年人的壓力水平略有上升，到 2020 年將達到 6.1。此外，輝瑞和克利夫蘭診所等主要市場領導的存在進一步促進了該地區睡眠障礙治療市場的成長。

睡眠障礙治療市場參與者

輝瑞正在推動醫療創新，讓世界變得更健康。該公司提供 Sonata®（Zaleplon）膠囊 CIV 作為睡眠障礙的治療藥物。無論男女，從年輕人到老年人都可以服用。賽諾菲公司是一家跨國製藥和醫療保健公司，總部位於巴黎。非昔硝唑是該公司與被忽視疾病藥物計劃（DNDi）合作開發的口服藥物，於2020年推出，是第一個治療昏睡病的口服藥物。武田製藥是一家總部位於日本的研發全球製藥公司。 Rozeram (TM) 是 FDA核准的非處方安眠藥。它選擇性地針對大腦 SCN 中存在的兩種受體。

市場主要發展

2023年6月，瑞士公司Idorsia推出了治療慢性失眠的革命性療法QUIVIVIQ（dalidrexant）。它是瑞士核准的第一個雙重Orexin受體拮抗，用於減少失眠症中的夜間多動性覺醒。 2022 年 9 月，沃克哈特醫院在孟買中央布蘭德開設了睡眠障礙診所。我們治療所有睡眠障礙，包括睡眠呼吸中止症、失眠、嗜睡、打鼾和睡眠呼吸中止呼吸中止症候群。 2021 年 12 月，韓國精神保健Start-UpsHoneynaps 宣布推出失眠治療數位治療業務，此外還監測、分析和診斷睡眠期間的生物訊號。該平台由用於診斷睡眠障礙的人工智慧軟體 SOMNUM 提供支援。

Many treatments are available for sleep disturbances, depending on the nature and underlying cause. However, it typically entails a mix of medical interventions and dietary adjustments. The higher prevalence of sleep disorders due to numerous underlying factors such as medication, frequent urination, and increasing depression disorder is driving the sleep disorder treatment market growth. Moreover, the growing alcohol consumption and increasing asthma cases are further expected to boost the sleep disorder treatment market.

Rising cases of sleep disorders

The rising cases of sleep disorders worldwide owing to various factors such as medications, frequent urination, and several others is a major growth driver in the sleep disorder treatment market. For instance, the World Economic Forum estimated that 62% of adults in 2019 globally felt they didn't get enough sleep at night. Moreover, in 2022, up to 70 million Americans suffered from a sleep issue as per the Sleep Association Organization. According to a Sleep Foundation survey conducted in 2022, 51.2% of short-sleepers claim that sleep issues run in their family. Moreover, insomnia is the most common sleep disorder in the US affecting around two-thirds of US adults as per the Sleep Doctor. The rising sleep disorder along with its adverse effects such as drowsiness and irritability is contemplated to boost the sleep disorder treatment market.

Growing Prevalence of Depression and Anxiety

Insomnia, or the difficulty of getting to sleep and staying asleep, is one of the typical symptoms of depression. Moreover, sleep disruptions can be brought on by psychological or physical trauma, metabolic issues, or other health issues. Therefore, the rising depression conditions among people are positively impacting the sleep disorder treatment market. An estimated 5% of adults' worldwide experience depression which equates to approximately 280 million people according to the WHO. In the United States, depression significantly contributes to death, morbidity, disability, and economic expenses. For instance, in 2020, 18.5% of U.S. adults reported ever receiving a diagnosis of depression according to the CDC.

Rising Asthma Cases and Alcohol Consumption

The stimulant effects of asthma drugs and the existence of other medical diseases, such as sleep disorders, may both contribute to insomnia in patients with asthma. The rising asthma cases thus, indicate the sleep disorder treatment market expansion. In 2019, 455 000 individuals died from asthma and an estimated 262 million people were affected by it according to the WHO. According to the Asthma MD Organization, with 2 million visits each year, asthma is responsible for 25% of all emergency room visits in the United States. Additionally, according to the Alcohol Organisation, alcohol abuse causes issues with both sleep quantity and quality, and alcoholics frequently experience insomnia the rising alcohol consumption poses a serious threat to sleep quality thereby propelling the sleep disorder treatment market. For instance, 5 million Australians aged 18 and older (one in four) consumed more alcohol than the recommended amount for adults in Australia in 2020-21 as per the Australian Bureau of Statistics.

Opportunities in the Market

The growth factors such as the higher prevalence of sleep disorders due to several factors provide an immense opportunity for sleep disorder treatment market expansion. Additionally, the increased awareness among people about the adverse effects of sleep disorders through numerous awareness programs organized by institutions is further propelling the sleep disorder treatment market thereby providing an opportunity to enter the market. Sleep Awareness Week® is organized by Sleep Foundation every year for the last 25 years. The foundation shares insightful data about how people have slept over the previous year and offers evidence-based guidance on the advantages of getting enough sleep and how it affects health and well-being during Sleep Awareness Week. Additionally, the CDC awarded a 3-year grant from 2021-2024 to focus on expanding education and awareness of obstructive sleep apnea. Furthermore, the rising living standards and health consciousness are also augmenting the sleep disorder treatment market growth.

North America is expected to grow significantly

The North American region is expected to hold a significant share of the sleep disorder treatment market during the forecast period. Various factors attributed to such a share are rising disease awareness and diagnosis rates, as well as busy lifestyles. Adults assessed their stress levels as 5.0 on a scale of 1 to 10 in 2020, according to a survey conducted by the American Psychological Association (APA). The last two years saw a minor increase in stress levels among Gen Z adults, and by 2020, it to reach 6.1. Moreover, the presence of major market leaders such as Pfizer, and Cleveland Clinic further aids the sleep disorder treatment market growth in the region.

Sleep Disorder Treatment Market Players

Pfizer advances in medical innovation to make the world a healthier place. Sonata® (zaleplon) capsule CIV is offered by the company for sleep disturbances. It can be taken by both men and women of the younger and elderly generations.
Sanofi SA, headquartered in Paris is a multinational pharmaceutical and healthcare company. The oral drug fexinidazole developed by the company in collaboration with the Drugs for Neglected Diseases initiative (DNDi) was launched in 2020 as the first all-oral treatment of sleeping sickness.
Takeda Pharmaceuticals is a global research and development-driven pharmaceutical company based out of Japan. Rozeram™ is FDA approved non-scheduled prescription sleep medication. It selectively targets two receptors in the brain SCN.

Key Market Developments

In June 2023, QUVIVIQ (daridorexant), a groundbreaking medication for chronic insomnia problems, was introduced by Idorsia in Switzerland. It is Switzerland's first approved dual orexin receptor antagonist that decreases nighttime overactive wakefulness in insomnia.
In September 2022, Wockhardt Hospitals launched a Sleep Disorder Clinic at Mumbai Central Brand. It is open to deal with all kinds of sleep disorders such as sleep apnea, insomnia, hypersomnia, snoring, parasomnia, and others.
In December 2021, a Korean mental healthcare startup, HoneyNaps announced the opening of a digital therapeutics business for the treatment of insomnia in addition to monitoring, analyzing, and diagnosing inter-sleep bio-signals. The platform is enabled with AI software for diagnosing sleep diseases named SOMNUM.

Segmentation:

By Drug Type

Benzodiazepines
Nonbenzodiazepines
Antidepressants
Orexin Antagonists
Melatonin Antagonists
Other Drug Types

By Application

Insomnia
Sleep Apnea
Narcolepsy
Circadian Disorders
Other Applications

By Payor

Public Health Insurance
Private Health Insurance

By Geography

North America
United States
Canada
Mexico
South America
Brazil
Argentina
Others
Europe
United Kingdom
Germany
France
Spain
Others
Middle East and Africa
Saudi Arabia
UAE
Israel
Others
Asia Pacific
Japan
China
India
South Korea
Indonesia
Thailand
Others

1. INTRODUCTION

1.1. Market Overview
1.2. Market Definition
1.3. Scope of the Study
1.4. Market Segmentation
1.5. Currency
1.6. Assumptions
1.7. Base, and Forecast Years Timeline

2. RESEARCH METHODOLOGY

2.1. Research Data
2.2. Assumptions

3. EXECUTIVE SUMMARY

3.1. Research Highlights

4. MARKET DYNAMICS

4.1. Market Drivers
4.2. Market Restraints
4.3. Porter's Five Force Analysis
- 4.3.1. Bargaining Power of Suppliers
- 4.3.2. Bargaining Power of Buyers
- 4.3.3. Threat of New Entrants
- 4.3.4. Threat of Substitutes
- 4.3.5. Competitive Rivalry in the Industry
4.4. Industry Value Chain Analysis

5. SLEEP DISORDER TREATMENT MARKET BY DRUG TYPE

5.1. Introduction
5.2. Benzodiazepines
5.3. Nonbenzodiazepines
5.4. Antidepressants
5.5. Orexin Antagonists
5.6. Melatonin Antagonists
5.7. Other Drug Types

6. SLEEP DISORDER TREATMENT MARKET BY APPLICATION

6.1. Introduction
6.2. Insomnia
6.3. Sleep Apnea
6.4. Narcolepsy
6.5. Circadian Disorders
6.6. Other Applications

7. SLEEP DISORDER TREATMENT MARKET BY PAYOR

7.1. Introduction
7.2. Public Health Insurance
7.3. Private Health Insurance

8. SLEEP DISORDER TREATMENT MARKET BY GEOGRAPHY

8.1. Introduction
8.2. North America
- 8.2.1. United States
- 8.2.2. Canada
- 8.2.3. Mexico
8.3. South America
- 8.3.1. Brazil
- 8.3.2. Argentina
- 8.3.3. Others
8.4. Europe
- 8.4.1. United Kingdom
- 8.4.2. Germany
- 8.4.3. France
- 8.4.4. Spain
- 8.4.5. Others
8.5. The Middle East and Africa
- 8.5.1. Saudi Arabia
- 8.5.2. UAE
- 8.5.3. Israel
- 8.5.4. Others
8.6. Asia Pacific
- 8.6.1. Japan
- 8.6.2. China
- 8.6.3. India
- 8.6.4. South Korea
- 8.6.5. Indonesia
- 8.6.6. Thailand
- 8.6.7. Others